A Sleep Extension Pilot Study in Adults With Obesity
A 16-Week Sleep Extension Pilot Study in Adults With Obesity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Alyssa M Minnick, Ph.D.
- Phone Number: 215-573-2517
- Email: alyssa.minnick@pennmedicine.upenn.edu
Study Contact Backup
- Name: Kelly C Allison, Ph.D.
- Phone Number: 215-898-2823
- Email: kca@pennmedicine.upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults, aged 18-50 years old,
- All genders
- Body Mass Index within the obese weight status (BMI of ≥ 30 kg/m2)
- Short sleep duration, defined as sleeping, on average, <6.5 hours/night for at least 5 nights/week
- Sleep patterns must be stable for the past 6 months
- Weight must be stable (+/- 10 lb) for the past 6 months
- If taking medication for medical or mental health conditions, the condition must be well-controlled with stable dosage (i.e., at least 3 months)
- Note: Individuals with and without insomnia will be eligible to participate to increase generalizability of the findings. Also, individuals with known obstructive sleep apnea that is being treated and individuals who fall below the "very high risk" category for obstructive sleep apnea (on the ARES screening questionnaire) will be included.
- Participants must provide a completed form for study participation from their primary care provider to confirm that it is safe from a medical perspective
Exclusion Criteria:
- Specific chronic sleep disorders (e.g., untreated or at very high risk for obstructive sleep apnea, restless leg syndrome, parasomnias, narcolepsy, central apnea, chronic fatigue syndrome, or fibromyalgia)
- Extreme chronotype (i.e., extreme morning or evening sleep patterns)
- Work schedule that is not compatible with sleep habit changes (e.g., night shifts, rotating shift work, or long driving)
- Chronic use of sleep aid or anticonvulsant medications
- Chronic organ disorders (e.g., untreated or uncontrolled diabetes, other endocrine disorders, COPD, chronic cardiac arrhythmia, uncontrolled hypertension or gastro-esophageal disorders)
- Current enrollment in a weight loss program or any active weight loss attempt (e.g., self-directed diet/exercise, over-the-counter supplements, weight management medication)
- History of bariatric surgery (with the exception of an adjustable gastric band that has been removed)
- Mental health disorders judged severe (e.g., major depression, eating disorders, anxiety disorders, bipolar disorder/mania, schizophrenia, active suicidal ideation)
- Substance use (e.g., illicit drugs, marijuana dependence, excessive caffeine intake, smoking/tobacco use)
- Planned move outside of the Philadelphia area in the next 6 months
- Planned travel across time zones during the study period
- Family factors that may interfere with adherence to the study protocol (e.g., infants and young children that consistently disrupt their sleep schedule; partner, other individuals, or pets that would make compliance difficult)
- Pregnancy or lactation or plans to become pregnant during the study period
- Menopause
- Any other contraindication to participation as determined by the study team
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Sleep Extension Intervention
All participants will receive the 16-week sleep extension intervention aimed to lengthen nighttime sleep duration by at least 30-60 minutes per night.
No prescription for daily calorie/dietary intake or physical activity will be provided in this study, except behaviors consistent with sleep hygiene recommendations.
|
The 16-week protocol includes 11 total individual visits that integrate applicable elements of Cognitive Behavioral Therapy for Insomnia (CBT-I) and health behavior change theory.
The first 6 weeks include weekly sessions (~45 minutes each) focused on psychoeducation about sleep, goal-setting and self-monitoring, stimulus control, addressing cognitive and somatic arousal, sleep hygiene, and challenging negative thoughts about sleep.
Sleep restriction will also be used in specific cases where sleep efficiency is low (<85%).
The remaining 10 weeks include briefer biweekly visits (5 visits, ~15-20 minutes each) to reinforce health behavior change strategies through topics such as problem-solving barriers, utilizing social support, identifying setbacks and creating an action plan, and relapse prevention.
Self-reported sleep diary data and subjective sleepiness will be collected at each visit.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of intervention session attendance
Time Frame: Baseline to Week 16 of the intervention
|
The percentage of sessions attended by participants across the 16-week intervention
|
Baseline to Week 16 of the intervention
|
|
Percentage of participants who complete the study
Time Frame: Baseline to Week 16 of the intervention
|
The percentage of participants who complete the final Week 16 visit
|
Baseline to Week 16 of the intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in nighttime sleep duration
Time Frame: Baseline to Week 16 of the intervention
|
Average nighttime sleep duration as measured by actigraphy during a 1-week monitoring period
|
Baseline to Week 16 of the intervention
|
|
Change in weight
Time Frame: Baseline to Week 16 of the intervention
|
Weight as measured in kilograms
|
Baseline to Week 16 of the intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Kelly C Allison, Ph.D., University of Pennsylvania
- Principal Investigator: Philip Gehrman, Ph.D., University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 852866
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.